Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,113 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neuromuscular Disease Clear all

Conditions: Cancer-related Problem/Condition, Neurotoxicity, Pain, Peripheral Neuropathy
Interventions: electrical stimulation pain therapy, questionnaire administration; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: COPD, Emphysema, Sarcopenia
Interventions: Multidisciplinary clinic evaluation, COPD standard of care; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: Christine Barr; Other
Eligibility: 18 Years to 89 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
Interventions: taldefgrobep alfa, Placebo; Drug
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years to 21 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 30
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more

Conditions: Medically Unexplained Chronic Fatigue, Chronic Fatigue Syndrome
Interventions: Cognitive-behavioral self-management, Symptom monitoring; Behavioral
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Memantine; Drug
Lead sponsor: Phoenix Neurological Associates, LTD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Duchenne Muscular Dystrophy
Interventions: Aim 2 Exercise group, Aim 1 Exercise Dosing, Aim 2 Control group; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 7 Years to 10 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Sciatica, Radiculopathy, Spinal Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Intervertebral Disk Displacement
Interventions: Physical therapy rehabilitation; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Neuropathic Pain
Interventions: oxytocin 100 micrograms, Normal Saline (preservative free); Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chronic Fatigue Syndrome (CFS)
Interventions: Placebo condition, Molecular hydrogen produced by a metallic magnesium tablet, consumed 3x a day dissolved in water. Treatment duration is 16 weeks.; Dietary Supplement
Lead sponsor: Fred Friedberg; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Sarcopenia
Interventions: bimagrumab, placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 70 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 17
States / cities: Little Rock, Arkansas • Cypress, California • La Jolla, California + 14 more

Conditions: Sarcopenia, Sarcopenia in Elderly, Age-associated Muscle Loss
Interventions: Experimental: External Focus, Other: Internal Focus; Behavioral
Lead sponsor: Creighton University; Other
Eligibility: 60 Years to 95 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Chronic Nociceptive Pain, Neuropathic Pain, Non-cancer Pain
Interventions: Oxymorphone ER; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Pain, Hip Pain, Ankle Pain, Lumbopelvic Pain
Interventions: lumbosacral joint manipulation, lumbar passive range of motion, No active intervention; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 50 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Severe Spasticity
Interventions: Gablofen® 3 mg/mL (baclofen injection), SynchroMed® II Programmable Pump; Drug · Device
Lead sponsor: Piramal Critical Care, Ltd.; Industry
Eligibility: 4 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 13
States / cities: Little Rock, Arkansas • Loma Linda, California • Miami, Florida + 10 more

Conditions: Post Herpetic Neuralgia
Interventions: NXN-462, Placebo; Drug
Lead sponsor: NeurAxon Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more

Conditions: HSP, Hereditary Spastic Paraplegia, Hereditary Spastic Paraparesis, Hereditary Spastic Paraplegia Type 50, Hereditary Spastic Paraplegia Type 47, Hereditary Spastic Paraplegia Type 51, Hereditary Spastic Paraplegia Type 52, SPG47, AP4B1, Neurogenetic Disorders, Neurodevelopmental Conditions, Movement Disorders, Gene Therapy
Interventions: BFB-101 (AAV9-CBh-AP4B1); Biological
Lead sponsor: BlackfinBio Ltd; Industry
Eligibility: 12 Months to 60 Months
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Neuropathy, Painful; Diabetic Neuropathies
Interventions: AZD5213 + pregabalin, Placebo, pregabalin capsules; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 9
States / cities: Clearwater, Florida • Orlando, Florida • Newnan, Georgia + 6 more

Conditions: Muscle Soreness
Interventions: Cannabidiol cream, Placebo cream; Other
Lead sponsor: Joseph Pastina; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Lexington, Kentucky

Conditions: Amyloidosis
Interventions: Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 14
States / cities: La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 10 more

Conditions: Drop Foot
Interventions: Infiltration of D5W; Drug
Lead sponsor: US Neuropathy Centers; Other
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: Weakness, Muscle
Interventions: Blood flow restriction training, No blood flow restriction training; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Spinal; Nerve Root, Pain, Pelvic Pain, Regional Pain Syndrome, Chronic Pain Syndrome, Complex Regional Pain Syndromes
Interventions: dorsal root ganglion neuromodulation; Device
Lead sponsor: KM Clinical Research Group; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Murrieta, California

Conditions: Hypogonadism, Male, Fatigue Syndrome, Chronic
Interventions: Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], placebo; Drug · Other
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 54 Years · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Search by objective public record fields.

Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer

Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD

Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

Fatigue Self-Management in Primary Care

Memantine Therapy in Amyotrophic Lateral Sclerosis

Strength Training in Duchenne Muscular Dystrophy

The Value of Traction in Treatment of Lumbar Radiculopathy

Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain

Controlled Trial of Hydrogen Water as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Dose Range Finding Study of Bimagrumab in Sarcopenia

The Influence of Movement Velocity Biofeedback on Muscle Activation and Self Perception in Older Adults With Sarcopenia

A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone

Effects of Lumbosacral Joint Mobilization/Manipulation on Lower Extremity Muscle Neuromuscular Response

Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

Topical CBD's Effects on Soreness and Performance

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Can the Phoenix Sign be Elicited With D5W

Blood Flow Restriction Training for People With Disabilities

Quality of Life and Pain Changes Due to DRG Stimulation for Chronic Pain

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone